| SETD2: an epigenetic modifier with tumor suppressor functionality J Li, G Duns, H Westers, R Sijmons, A van den Berg, K Kok Oncotarget 7 (31), 50719, 2016 | 159 | 2016 |
| ZDHHC11 and ZDHHC11B are critical novel components of the oncogenic MYC-miR-150-MYB network in Burkitt lymphoma A Dzikiewicz-Krawczyk, K Kok, I Slezak-Prochazka, JL Robertus, ... Leukemia 31 (6), 1470-1473, 2017 | 56 | 2017 |
| Functional studies on primary tubular epithelial cells indicate a tumor suppressor role of SETD2 in clear cell renal cell carcinoma J Li, J Kluiver, J Osinga, H Westers, MB van Werkhoven, MA Seelen, ... Neoplasia 18 (6), 339-346, 2016 | 34 | 2016 |
| Developing ultrasensitive library-aliquot-based droplet digital PCR for detecting T790M in plasma-circulating tumor DNA of non-small-cell-lung-cancer patients K Yang, J Li, J Zhao, P Ren, Z Wang, B Wei, B Dong, R Sun, X Wang, ... Analytical chemistry 90 (19), 11203-11209, 2018 | 24 | 2018 |
| Combined plasma and tissue genotyping of EGFR T790M benefits NSCLC patients: a real‐world clinical example B Wei, C Zhao, J Li, J Zhao, P Ren, K Yang, C Yan, R Sun, J Ma, Y Guo Molecular Oncology 13 (5), 1226-1234, 2019 | 13 | 2019 |
| Uncommon EGFR G724S mutations arise in non-small-cell lung cancer patients with acquired resistance to first-generation EGFR-TKIs J Li, Z Wang, HJM Groen, J Zhao, P Wang, C Zhang, K Yang, Y Guo, J Ma Lung cancer 118, 173-175, 2018 | 11 | 2018 |
| Identification of BRCA1:c.5470_5477del as a Founder Mutation in Chinese Ovarian Cancer Patients J Li, S Han, C Zhang, Y Luo, L Wang, P Wang, Y Wang, Q Xia, X Wang, ... Frontiers in Oncology 11, 655709, 2021 | 6 | 2021 |
| Case report: TP53 and RB1 loss may facilitate the transformation from lung adenocarcinoma to small cell lung cancer by expressing neuroendocrine markers J Li, B Wei, J Feng, X Wu, Y Chang, Y Wang, X Yang, H Zhang, S Han, ... Frontiers in endocrinology 13, 1006480, 2022 | 3 | 2022 |
| A single-cell atlas of tumor-infiltrating immune cells in pancreatic ductal adenocarcinoma H Wang, L Chen, L Qi, N Jiang, Z Zhang, H Guo, T Song, J Li, H Li, ... Molecular & Cellular Proteomics 21 (8), 2022 | 3 | 2022 |
| Characterization of Synonymous BRCA1: c. 132C> T as a Pathogenic Variant J Li, P Wang, C Zhang, S Han, H Xiao, Z Liu, X Wang, W Liu, B Wei, J Ma, ... Frontiers in oncology 11, 812656, 2022 | | 2022 |
| Toxic Epidermal Necrolysis-Like Reaction Following Combination Therapy With Camrelizumab and Apatinib for Advanced Gallbladder Carcinoma Y Yang, J Li, BG Till, J Wang, B Zhang, H Wang, H Huang, T Li, Q Gao, ... Frontiers in Oncology 11, 728253, 2021 | | 2021 |
| An optimized workflow for a fast molecular diagnosis of non-small cell lung cancer. B Wei, J Li, P Ren, Y Chang, C Zhao, Q Xia, HJM Groen, J Ma, Y Guo Journal of Clinical Oncology 37 (15_suppl), e13139-e13139, 2019 | | 2019 |
| The targetable mutation landscape of Chinese patients with non-small cell lung cancer. J Li, C Zhang, J Zhao, Z Wang, B Wei, R Sun, HJM Groen, J Ma, Y Guo Journal of Clinical Oncology 37 (15_suppl), e13018-e13018, 2019 | | 2019 |
| Paraffin embedded tissue as valuable and challenging resource for studying intratumoral genetic heterogeneity of clear cell renal cell carcinoma P Ferronika, J Bergsma, J Li, MM Terpstra, AM Lelieveld-Kors, R Danarto, ... European Journal of Cancer 50, S78, 2014 | | 2014 |
| 450: The consequence of SETD2 mutation in clear cell renal cell carcinoma progenitor cells J Li, J Osinga, P Ferronika, MB Van Werkhoven, MM Terpstra, ... European Journal of Cancer, S109, 2014 | | 2014 |
Anke van den BergProfessor of Molecular biology of malignant B cell lymphomas, University of Groningen, UniversityVerified email at umcg.nl
